Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899198 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL3120563 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL3117563 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL30132824 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL13730578 | 0.96 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL3520660 | 0.96 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL3525506 | 0.96 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL3739499 | 0.95 | HSP90AA1 (0.91) | HSP90AA1HSP90AB1 | |
| SCHEMBL14733547 | 0.94 | HSP90AA1 (0.89) | HSP90AA1HSP90AB1 | |
| SCHEMBL3124809 | 0.94 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387492-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | FUSION PHARMACEUTICALS INC (CA) | 2025-12-25 | — | — | US | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| CN-119236123-A | HSP 90-targeting conjugates and formulations thereof | 融合制药公司 | 2025-01-03 | — | — | CN | claimed |
| WO-2024172631-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | 주식회사 카나프테라퓨틱스 | 2024-08-22 | — | — | WO | claimed |
| EP-3689411-B1 | METHOD FOR MANUFACTURING A MICRONEEDLE ARRAY | FUJIFILM CORP (JP) | 2024-04-24 | — | — | EP | claimed |
| CN-116077660-A | A method for treating cancer | 杭州百可生物科技有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-115990253-A | Method for reducing drug resistance of cancer patient | 杭州百可生物科技有限公司 | 2023-04-21 | — | — | CN | claimed |
| CN-115957328-A | Pharmaceutical composition for treating leukemia and leukemia treatment method | 杭州百可生物科技有限公司 | 2023-04-14 | — | — | CN | claimed |
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-08-04 | — | — | US | claimed |
| US-20220096640-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-03-31 | — | — | US | claimed |
| WO-2022047008-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-02-03 | — | — | US | claimed |
| US-20260144196-A1 | AGRICULTURAL GREENHOUSE, PLANT CULTIVATION METHOD USING THE SAME, AND HEAT-RAY REFLECTING FILM STRUCTURE | TOYOBO CO., LTD. (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-26 | — | — | US | disclosed |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-05 | — | — | US | disclosed |
| US-12606746-B2 | Composition, optically anisotropic layer, liquid crystal cell, liquid crystal display device, sensor, lens, switching element, isolator, and camera | FUJIFILM CORPORATION (JP) | 2026-04-21 | — | — | US | disclosed |
| US-11241500-B2 | HSP90-targeting conjugates and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-02-03 | — | — | US | disclosed |
| CN-114007671-A | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancer of epithelial tissue | 休斯敦大学体系 | 2022-02-01 | — | — | CN | disclosed |
| WO-2022019920-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | VERASTEM, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | NTRK1, NTRK3, NTRK2 | HSP90AA1 1786/4885HSP90AB1 1768/4885 |
| US-20220096640-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885 |
| US-12606746-B2 | Composition, optically anisotropic layer, liquid crystal cell, liquid crystal display device, sensor, lens, switching element, isolator, and camera | CRYAA, SSB, UACA | HSP90AA1 1606/4885HSP90AB1 2306/4885 |
| US-20260144196-A1 | AGRICULTURAL GREENHOUSE, PLANT CULTIVATION METHOD USING THE SAME, AND HEAT-RAY REFLECTING FILM STRUCTURE | CRY2, CRY1, WAPL | HSP90AA1 680/4885HSP90AB1 480/4885 |
| US-11241500-B2 | HSP90-targeting conjugates and formulations thereof | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885 |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 1/4885 |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885 |
| US-20250387492-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885 |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | POU2F1, POU2F2, PARP2 | HSP90AA1 3101/4885HSP90AB1 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.